Form 4: Sutro Biopharma Executive Jane Chung Reports Stock Transactions
SEC Form 4 Filing
Jane Chung, President and COO of Sutro Biopharma, reports the vesting and subsequent tax withholding of shares related to restricted stock units.
Summary
- On March 4, 2024, Jane Chung, President and COO of Sutro Biopharma, had 7,875 shares of common stock vest from restricted stock units (RSUs).
- Simultaneously, 2,209 shares were withheld by the issuer to cover income tax obligations related to the RSU vesting at a price of $4.79.
- Following these transactions, Chung directly owns 42,201 shares of Sutro Biopharma common stock and 15,750 RSUs.
- The RSUs vest annually, with 1/4th of the total award vesting each year beginning on March 4, 2023, contingent upon continued service.
Sentiment
Score: 5
Explanation: This is a routine regulatory filing reflecting standard compensation practices. It doesn't inherently indicate positive or negative sentiment.
Future Outlook
The document does not contain any specific forward-looking statements or guidance.
Industry Context
Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. This filing indicates activity related to equity compensation.
Key Dates
| Date | Description |
|---|---|
| 03/04/2023 | RSUs vest as to 1/4th of the total award annually beginning on this date. |
| 03/04/2024 | Date of the reported transactions: vesting of RSUs and tax withholding. |
| 03/06/2024 | Date of the form filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.